Evonik Industries/€EVK
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Evonik Industries
Evonik Industries AG, a German multinational, specializes in producing specialty chemicals, primarily focusing on consumer goods, animal nutrition, and pharmaceuticals. Founded in 1873, the company operates globally and is structured into multiple segments including Specialty Additives, Nutrition & Care, and Smart Materials among others. As a publicly traded entity, it is listed on the Frankfurt Stock Exchange under the ticker EVK.
- Ticker
- €EVK
- Sector
- Materials
- Primary listing
- XETRA
- Employees
- 30,356
- Headquarters
- Essen, Germany
- Website
- evonik.com
EVK Metrics
BasicAdvanced
€9.8B
81.10
€0.26
0.54
€1.00
4.75%
Price and volume
Market cap
€9.8B
Beta
0.54
52-week high
€21.66
52-week low
€12.50
Average daily volume
1.5M
Dividend rate
€1.00
Financial strength
Current ratio
1.496
Quick ratio
0.622
Long term debt to equity
0.446
Total debt to equity
0.563
Dividend payout ratio (TTM)
385.12%
Interest coverage (TTM)
5.81%
Profitability
EBITDA (TTM)
1,752
Gross margin (TTM)
24.91%
Net profit margin (TTM)
0.86%
Operating margin (TTM)
6.58%
Effective tax rate (TTM)
50.19%
Revenue per employee (TTM)
€460,000
Management effectiveness
Return on assets (TTM)
3.22%
Return on equity (TTM)
1.60%
Valuation
Price to earnings (TTM)
81.105
Price to revenue (TTM)
0.695
Price to book
1.25
Price to tangible book (TTM)
3.56
Price to free cash flow (TTM)
10.407
Free cash flow yield (TTM)
9.61%
Free cash flow per share (TTM)
2.024
Dividend yield (TTM)
4.75%
Forward dividend yield
4.75%
Growth
Revenue change (TTM)
-4.05%
Earnings per share change (TTM)
-71.69%
3-year revenue growth (CAGR)
-6.22%
10-year revenue growth (CAGR)
0.88%
3-year earnings per share growth (CAGR)
-25.66%
10-year earnings per share growth (CAGR)
-16.35%
3-year dividend per share growth (CAGR)
-5.10%
10-year dividend per share growth (CAGR)
-1.39%
What the Analysts think about EVK
Analyst ratings (Buy, Hold, Sell) for Evonik Industries stock.
Analyst projections of the future price of Evonik Industries stock.
Bulls say / Bears say
Second-quarter adjusted EBITDA rose 24% to €630 million, and Evonik lifted its 2026 forecast to €2.0–2.2 billion from €1.7–2.0 billion. Higher volumes and prices point to a sharp near-term earnings recovery. (Evonik)
Evonik plans to direct investment towards growth areas such as healthcare and biotechnology while using its restructuring programme to lower costs. If it delivers, this could improve the portfolio’s growth mix and competitiveness over time. (Evonik)
Moody’s raised Evonik’s long-term rating to Baa1 with a stable outlook, citing leverage below 2.5 times and stronger financial discipline. That upgrade supports the case that balance-sheet risk is easing. (Evonik)
A key boost to earnings came from supply-chain disruption that constrained Asian rivals, and Evonik said this tailwind should fade as shipping normalises. The company’s higher 2026 forecast may therefore overstate the earnings run-rate beyond this year. (Evonik)
The first-quarter comparison showed underlying weakness before the later rebound: sales fell 9%, volumes declined 2% and net income dropped to €125 million from €233 million. This leaves the recovery vulnerable if demand and pricing do not hold up. (Evonik)
Data summarised monthly by Lightyear AI. Last updated on 22 Oct 2026.
EVK Financial Performance
Revenues and expenses
EVK Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing EVK
AllEURUSDGBP
Fund name | Fund size | €EVK weighting |
|---|---|---|
iShares MDAX€EXS3 | €1.5B | 3.74% |
iShares MDAX€EXID | €34M | 3.74% |
iShares STOXX Europe 600 Chemicals€EXV7 | €103M | 2.48% |
Vanguard Germany All Cap£VGER | €258M | 0.29% |
SPDR MSCI World Materials€WMAT | $206M | 0.21% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.